The global respiratory syncytial virus respiratory syncytial virus treatment market is undergoing rapid growth, driven by ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

With the U.S. FDA’s approval of Enflonsia (cesrovimab) to prevent respiratory syncytial virus (RSV) infection lower ...

Approval of Enflonsia was based on data from the Phase IIb/III CLEVER trial, which showed a 60.5% reduction in medically ...

Further, the study showed that nirsevimab’s effect was less pronounced in older children (between six and 23 months), ...

As winter settles over Australia, it's not just the drop in temperature we notice—there's also a sharp rise in respiratory ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Here’s what causes colds to spread so easily, how long they are usually contagious and how they’re most commonly treated.

Enflonsia is the first FDA-approved respiratory syncytial virus (RSV) preventative for infants, regardless of weight, according to the news release.

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.